

Emerging Challenges In Primary Care: 2016

Activity Evaluation Summary

CME Activity: Emerging Challenges in Primary Care: 2016

Saturday, October 22, 2016 Marriott San Diego La Jolla

San Diego, CA

Course Director: Gregg Sherman, MD

Date of Evaluation Summary: November 4, 2016



In October 2016, the National Association for Continuing Education (NACE) sponsored a CME program, *Emerging Challenges in Primary Care: 2016*, in San Diego, CA.

This educational activity was designed to provide primary care physicians, nurse practitioners, physician assistants and other primary care providers the opportunity to learn about varied conditions such as prostate cancer screening, overactive bladder, ADHD in adults, heart failure, and hypercholesterolemia.

In planning this CME activity, the NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

One hundred ninety two one healthcare practitioners registered to attend *Emerging Challenges in Primary Care: 2016* in San Diego, CA and two hundred forty one registered to participate in the live simulcast. Two hundred three healthcare practitioners actually participated in the conference: one hundred twelve attended the conference in San Diego, CA and ninety one participated via the live simulcast. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. One hundred ninety seven completed forms were received. The data collected is displayed in this report.

CME ACCREDITATION

The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 3.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 3.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 7 contact hours of continuing education (which includes 2.25 pharmacology hours).

Maintenance of Certification: Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 7 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity providers' responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Through the American Board of Medical Specialties ("ABMS") and Association of American Medical Colleges' ("AAMC") joint initiative (ABMS MOC Directory) to create a wide array of Maintenance of Certification ("MOC") Activities, Emerging Challenges in Primary Care has met the MOC requirements as a MOC Part II CME Activity by the following ABMS Member Boards: American Board of Family Medicine and American Board of Preventive Medicine.

What is your professional degree?

	<u>9</u>	
Label	Frequency	Percent
MD	91	46%
DO	3	2%
NP	69	35%
PA	24	12%
RN	7	4%
Other	3	2%
Total	197	100%

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: Prostate Cancer:

Label	Frequency	Percent
None	34	18%
1-5	58	30%
6-10	41	21%
11-15	20	10%
16-20	12	6%
21-25	8	4%
> 25	21	11%
Total	194	100%

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: OAB:

Label	Frequency	Percent
None	26	13%
1-5	75	38%
6-10	42	22%
11-15	14	7%
16-20	20	10%
21-25	8	4%
> 25	10	5%
Total	195	100%

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: ADHD:

Label	Frequency	Percent
None	41	21%
1-5	91	47%
6-10	32	16%
11-15	17	9%
16-20	5	3%
21-25	7	4%

> 25	1	1%
Total	194	100%

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: Heart Failure:

Label	Frequency	Percent
None	25	13%
1-5	67	35%
6-10	36	19%
11-15	20	10%
16-20	19	10%
21-25	9	5%
> 25	18	9%
Total	194	100%

Indicate the number of patients you see each week in a clinical setting regarding each

therapeutic area listed: Hypercholesterolemia:

Label	Frequency	Percent
None	12	6%
1-5	26	14%
6-10	29	15%
11-15	28	15%
16-20	26	14%
21-25	26	14%
> 25	43	23%
Total	190	100%

Upon completion of this activity, I can now: Recognize the prevalence and risk factors of prostate cancer; Compare the USPSTF, AUA and NCCN guidelines on screening; Understand the use of PSA and biomarkers; Develop a logical approach to screening for prostate cancer in a primary care setting.

Label	Frequency	Percent
Yes	182	93%
Somewhat	14	7%
Not at all	0	0%
Total	196	100%

Upon completion of this activity, I can now: Identify the patient with overactive bladder (OAB) in the office of the primary care physician (PCP) with a simple history, physical and appropriate labs; Identify interventions that can optimize OAB treatment and improve patient satisfaction; Discuss the strategy of matching treatment of OAB based on specific patient needs; Optimize adherence by enhancing communication in order to engage and partner with patients in the treatment plan

Label	Frequency	Percent
Yes	173	90%
Somewhat	20	10%
Not at all	0	0%
Total	193	100%

Upon completion of this activity, I can now: Describe ADHD symptom profiles and common presentations in a primary care setting; Identify risks for coexisting disorders in adult patients with ADHD with emphasis on anxiety disorders, mood disorders, and substance use/abuse disorders; Implement appropriate pharmacologic treatment for adults diagnosed with ADHD designed to improve compliance, minimize side effects and maximize outcomes in a busy primary care setting; Use adult ADHD assessment and treatment tools for assessment, treatment and follow-up monitoring.

Label	Frequency	Percent
Yes	166	87%
Somewhat	24	13%
Not at all	0	0%
Total	190	100%

Upon completion of this activity, I can now: Know the risk factors for heart failure and the role of biomarkers in diagnosis and treatment; Recognize the importance of heart rate in cardiovascular risk of heart failure; Utilize the most recent clinical evidence to inform their decisions for the management of heart failure; Identify approaches to facilitate early recognition and optimization of heart failure management?; Describe pathophysiologic factors contributing to increased risk of heart failure among African Americans and minorities.

Label	Frequency	Percent
Yes	164	88%
Somewhat	21	11%
Not at all	2	1%
Total	187	100%

Upon completion of this activity, I can now: Discuss the benefits of LDL-C lowering with pharmacologic therapies that improve cardiovascular outcomes; Define the appropriate use of non-statin medications in addition to statin therapy; Discuss the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction; Recognize and develop appropriate treatment strategies for special populations (women, elderly, ethnic minorities) that would benefit from lipid lowering therapy.

Label	Frequency	Percent
Yes	152	87%
Somewhat	22	13%
Not at all	0	0%
Total	174	100%

Overall, this was an excellent CME activity:

overally the true an executent one activity.		
Label	Frequency	Percent
Strongly Agree	147	76%
Agree	45	23%
Neutral	1	1%
Disagree	0	0%
Strongly Disagree	0	0%
Total	193	100%

Overall, this activity was effective in improving my knowledge in the content areas presented:

•		
Label	Frequency	Percent
Strongly Agree	151	78%
Agree	42	22%
Neutral	1	1%
Disagree	0	0%
Strongly Disagree	0	0%
Total	194	100%

As a result of this activity, I have learned new and useful strategies for patient care:

Label	Frequency	Percent
Strongly Agree	136	70%
Agree	53	27%
Neutral	4	2%
Disagree	0	0%
Strongly Disagree	0	0%
Total	193	100%

How likely are you to implement these new strategies in your practice?

Label	143	74%
Very Likely	35	18%
Somewhat likely	2	1%
Unlikely	13	7%
Not applicable	193	100%
Total	143	74%

When do you intend to implement these new strategies into your practice?

<u> </u>		ice iiice jeur praetiee i
Label	Frequency	Percent
Within 1 month	132	69%
1-3 months	33	17%
4-6 months	4	2%
Not applicable	23	12%
Total	192	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker:

Matt T. Rosenberg, MD – Prostate Cancer Screening:

Label	Frequency	Percent
Excellent	166	85%
Very Good	24	12%
Good	4	2%
Fair	1	1%
Unsatisfactory	0	0%
Total	195	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker:

Matt T. Rosenberg, MD – OAB:

Label	Frequency	Percent
Excellent	160	83%
Very Good	29	15%
Good	3	2%
Fair	1	1%
Unsatisfactory	0	0%
Total	193	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker: C.

Greg Mattingly, MD – ADHD:

Label	Frequency	Percent
Excellent	157	84%
Very Good	24	13%
Good	7	4%
Fair	0	0%
Unsatisfactory	0	0%
Total	188	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker:

Robert L. Gillespie, MD, FACC, FASE, FASNC – Heart Failure Part I:

Label	Frequency	Percent
Excellent	129	74%
Very Good	27	15%
Good	16	9%
Fair	3	2%
Unsatisfactory	0	0%
Total	175	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker:

Robert L. Gillespie, MD, FACC, FASE, FASNC – Heart Failure Part II:

Label	Frequency	Percent
Excellent	130	73%
Very Good	31	17%
Good	14	8%
Fair	2	1%
Unsatisfactory	1	1%
Total	178	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker:

Karol E. Watson, MD, PhD – Heart Failure Part II:

Label	Frequency	Percent
Excellent	135	77%
Very Good	30	17%
Good	7	4%
Fair	1	1%
Unsatisfactory	2	1%
Total	175	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker:

Karol E. Watson, MD, PhD – Hypercholesterolemia:

Label	Frequency	Percent
Excellent	128	76%
Very Good	29	17%
Good	9	5%
Fair	1	1%
Unsatisfactory	1	1%
Total	168	100%

To what degree do you believe that the subject matter was presented fair, balanced,

and free of commercial bias? Matt T. Rosenberg, MD – Prostate Cancer Screening:

Label	Frequency	Percent
Excellent	160	83%
Very Good	24	12%
Good	8	4%
Fair	1	1%
Unsatisfactory	0	0%
Total	193	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Matt T. Rosenberg, MD – OAB:

Label	Frequency	Percent
Excellent	155	81%
Very Good	28	15%
Good	7	4%
Fair	1	1%
Unsatisfactory	0	0%
Total	191	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Greg Mattingly, MD – ADHD:

Label	Frequency	Percent
Excellent	152	80%
Very Good	26	14%
Good	9	5%
Fair	2	1%
Unsatisfactory	0	0%
Total	189	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Robert L. Gillespie, MD, FACC, FASE, FASNC – Heart Failure Part 1.

Label	Frequency	Percent
Excellent	139	76%
Very Good	29	16%
Good	13	7%
Fair	1	1%
Unsatisfactory	0	0%
Total	182	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Robert L. Gillespie, MD, FACC, FASE, FASNC – Heart Failure Part II:

Label	Frequency	Percent
Excellent	137	77%
Very Good	30	17%
Good	11	6%
Fair	1	1%
Unsatisfactory	0	0%
Total	179	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Karol E. Watson, MD – Heart Failure II

Label	Frequency	Percent
Excellent	140	78%
Very Good	30	17%
Good	10	6%
Fair	0	0%
Unsatisfactory	0	0%
Total	180	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Karol E. Watson, MD – Hypercholesterolemia

in the or commercial black hards at wassen, the highest energe continue		
Label	Frequency	Percent
Excellent	291	80%
Very Good	59	16%
Good	15	4%
Fair	1	0%
Unsatisfactory	0	0%
Total	366	100%

Which statement(s) best reflects your reasons for participating in this activity:

Label	Frequency	Percent
Topics covered	163	34%
Location/ease of access	126	26%
Faculty	36	7%
Earn CME credits	157	33%
Total	482	100%

Future CME activities concerning this subject matter are necessary:

r didire the delivition concerning the dabject matter are necessary.		
Label	Frequency	Percent
Strongly agree	112	58%
Agree	66	34%
Neutral	15	8%
Disagree	0	0%
Strongly Disagree	1	1%
Total	194	100%

As a result of this activity, I have learned new strategies for patient care. List these strategies:

\sim			
Con	٦m	ρr	١t

- 1.5 PSA level/tibial nerve stimulation/biomarkers
- 1. Know how to use new agents for hyperchesterolemia down to goal
- 2. Select the right agents for all types of CHF
- 3. Detect and treat the adult ADHD properly
- 4. Select the right medicine for OAB

1Evaluate PSA over 1.5, Use biomarkers for elevated PSA, Use the BNP more appropriately in evaluating heart failure patients.

2-3-1

ADHD, HF

all

Apply the guidelines

Appropriate classes of medications for treatment of CHF and how to apply

Appropriate interpretation of PSA level, BNP for heart failure pts vs non-heart failure cause, lifestyle changes with OAB, recognizing ADHD and use of different medications

Appropriate therapy for hyperlipidemia beyond Statin.

Ask appropriate questions to identify conditions such as OAB, and not simply asking "how is your bladder control," since many patients are embarrassed to talk about it. I will also talk to the patient about PSA screening and why it's important.

At this point i am not sure about the strategies I would use.

Better apply the learned knowledge

Better assessment options, medication and treatment options

Better awareness of issues, better treatment ideas, planning, decision making

Better evaluation and management of patients with Heart Failure & hyperlipidemia

Better evaluation of risk factor

Adequate treatment guidelines

Better hx taking and confidence in first line medications and evidence based medications for AA populations

Better identifying problems and treating it

Better recognition of OAB; new drugs for heart failure and lipids; finally have a better grasp of why prostate cancer guidelines are the way they are

Better use of PSA testing, Rx for OAB

Better use PSA testing and use of bookmakers

Better management of OAB using 2 agent

Better HF management in the AA patient

Better management of hyperlipidemia using statins

Consider prostate cancer biomarkers if screening PSA >1.5

Continue this good strategy

Current Guidelines for screening and care of ADHD

Best med choices for Hypercholesteremia

Best choices for a variety of patients regarding CHF med combinations

Currwnt screening recommendations anm treatment measures for Prostate Cancer

Better methods to evaluate poatients for OAB in primary care

Currently I am working in medical education. However, I like to keep up CMEs if I decide to see patients. I am glad that I participated to get the updated guidelines. That information will still be useful in my lectures.

Diagnosing ADHD using the tools, Isosorbide and Hydralazine for African Americans

Diagnosis and treatment of ADHD

Differentiate or rule out diagnosis, decision making, drug therapies

Discuss important questions regarding symptoms with the patient

Employ validated questionnaires for patients to complete prior to seeing them

Encourage colleagues

Evaluate ADHD - using screening tools

Evaluation and treatment

Facts

For abnormal PSA, use biomarkers as a next step in screening. Use long acting agents for treating ADHD in adults

History taking and symptom eval.

How to diagnose the different medical conditions and treat my patients better. More therapeutic treatments to choose from.

How to recognize and manage all the cases discussed

I now know what to look for and how to treat when needed.

I will be better able to screen for OAB, ADHD, and Prostate CA.

I will modify my practice of screening for prostate cancer under AUA guidelines.

Increase diagnostic approaches

consider alternative strategies

ensure a complete history

Increased awareness about appropriate testing

Initiate shared decision with patient

Insurance is a barrier in implementing using biomarkers and such. Will do the best I can

Interesting, but I am Ophthalmologist with strong interest in general medicine - glad I attended, useful in practice

Latest evidenced based care practices.

Emerging Challenges in Primary Care: Update 2016

The speakers were fantastic; I particularly enjoyed the physician who presented on prostate cancer screening and OAB and ADHD. They were outstanding! Latest treatment modalities Latest treatments Learned about biomarkers for next step, awareness of OAB and ADHD Look for heart failure, ADHD, OAB Management of ADHD, statin therapy and about PSA values. More rational approach to using PSA and higher level screening for prostate cancer, will start using a screening tool for adult ADHD More screening Multifaceted N/A NA New guidelines New meds for HF and dyslipidemia - now I can use them with comfort. Use of biomarkers when PSA >1.5, combination therapy for OAB, stress treating ADHD instead of referring out Nothina OAB therapy. Implementing treatment for ADHD OAB-PTNM, biomarkers, ADHD-meds, CHF-meds Optimizing treatment for lipid lowering meds Order biomarkers in case of prostate cancer before surgery To take detailed history to diagnose OAB To follow up children, diagnosed with ADHD in order to provide treatment for them even in

adulthood

to pay closer attention to African American patients with HF (screening, education)

to extend usage of LDL lowering meds among patients with HF

Ordering biomarkers levels when PSA level is 1.5 or higher before ordering biopsies. Also ordering accurate Heart Failure medications when treating the African American population.

Perform biomarkers for abnormal PSA, ADHD questionnaire, more aware of heart failure treatments

Proper ID of OAB, heart failure

Prostate screening

treatment of dyslipidemia - new drug therapy

new drug for heart failure

PSA testing, ADHD screening

Questionnaire for ADHD

Recognizing patients at high risk, and involving the patient to develop a

treatment/management plan

Reinforced my current clinical approach to diagnosis and treatment

Risk for prostate cancer, adhd, heart failure

Screen for ADHD

Screen for ADHD. Better Rx for heart disease. Order biomarkers for high PSA

Screen for adult ADD.

Screening adults for ADHD with screening tools, treating AA with HF

Screening for ADHD; screen for depression as first sign for ADHD

PSA 1.5; Bio-markers for Prostate cancers

Bio-marker for Heart failure

Surveys for ADHD, use of SSRI's in ADHD, prostate screening, CHF treatments

TD ADHD with atypical antidepressant Wellbutrin. This is 1st line tx for ADHD.

Emerging Challenges in Primary Care: Update 2016

Lest PSA initially about incontinence and treat more often. Treat LDL to goals

The steps in the diagnosis, treatment, and follow-up of these common family practice diagnoses was clearly spelled out. Excellent PowerPoints.

The value of the psa for screeing for prostate ca

This seminar helps me to rethink each disease covered.

Thorough questioning

Tools for ADHD, new medication for treating heart failure, new treatment for OAB

Undertanding Biomarkers in Prostate Cancer. Ability to diagnosis & treat Adult ADHD, treat QAB, treat HF with current guidelines

Updated in diagnosis and treatment of prostate diseases,

ADHD, CHF, OAB

Use guidelines for heart failure and other treatment modalities to coordinate care.

Use long acting ADHD med only, not short acting for adults. Screen ADHD, use screening PSA in appropriate population

Use necessary effective diagnostic method, decide, treat properly, effectively

Use of biomarkers for prostate cancer. More emphasis of behavioral therapy for OAB. Use rating scales to diagnose and monitor ADHD. Use of newer HF meds. More aggressive statin use

Use of long acting stimulants in ADHD, new meds for treating CHF

Use of long acting stimulants instead of shorter acting

Use PSA and biomarker to screen prostate cancer. Implement pharmacologic treatment for adults diagnosed with ADHD. Use ADHD screening stools. Screen pt with OAB

Using biomarkers in patient with PSA >1.5

Using the updated information for early diagnosis and management

When and when not to order PSA on adult men,,to Screen for adult ADHD with handout. How to treat patients with heart failure to goal, new medications for treating heart failure and dyslipidemia

Will implement strategies discussed

Will implement what I learned to improve care of pts

What topics would you like to see offered as CME activities in the future?

Comment

- * WOMEN'S HEALTH
- * BIOTERRORISM / PREPAREDNESS
- * OUTPATIENT COMMON INFECTIONS & THOSE INCLUDING SEPSIS & THEIR MANAGEMENT/ INFECTIOUS DISEASE
- * SPINE/JOINT PAIN MANAGEMENT WITH CURRENT GUIDELINES
- * OBESITY, OPHTHALMOLOGY, COMMON DERMATOLOGIC DISEASES
- * AUTOIMMUNE (COMMON CASES), ENDOCRINOLOGY,

HYPOTHYROIDISM, ENT CASES, RHEUMATOID ARTHRITIS & OTHER METABOLIC DISEASES, ESRD,

Addiction, HepC, antibiotic resistance, MRSA

ADHD

ADHD/HF lectures were good

All Primary Care topics

Allergy and Asthma, Type II Diabetes

Alzheimer's, Dementia, Ortho, injection joint

Anv

Any Orthopedic, Dermatology (issues in Primary Care)

Emerging Challenges in Primary Care: Update 2016

Arrhythmias CAD Diabetes Atrial fibrillation, dermatology, and orthopedic topic. Chronic disease mgmt strategies to enhace outcomes. Chronic Kidney Disease. Dermatologic emergencies Common orthopedic problems, diabetes Current recommendations for blood pressure in patients over 50 Dermatology for the PCP, autoimmune disease for the PCP **Dermatology Nutrition** Dermatology, Prevalence and treatment for strep pharyngitis **Diabetes** Diabetes mgt BP mgt Sports injuries Common dermatological conditions EKG. Cardiovascular disease Functional medicine, botanicals, dermatology for PCP, addiction medicine Geriatric medicine Geriatrics GYN topics, Derm topics Hematosis, DUB, basic ortho assessment, review, insomnia, mood disorders Hereditary angioedema HIV HIV and STIs HIV concepts in Primary Care Pain modalities in Primary Care before referring to Pain management HPN, asthma, Bipolar Disorder, colorectal cancer Htn Hypertension treatments and lifestyle modifications. Hypertension. Age care concerns. Medical costs I am a women's health practitioner and incorporate primary care - so these talks this weekend where wonderful and informative. More wonen's health would be great though the issues you have covered are for all people and poopulations, may women's issues in a general context IBS. AFib. CHF. Obesity. HTN ihss Infectious Disease and Dermatology for Primary Care Infectious diseases Insomnia, PTSD Kidney failure, woman's health, thyroid and endocrine disorders.breast cancer and other type of cancers Management of hypertension Management of hyperthyroidism Management of obesity Role of nutrition, exercise and life style in prevention of common diseases such as DM, HTN, CAD, cancer Management of refractory HTN Migraines, obesity, diet controlled

More of latest developments in Cardiology More on ADHD - how to determine how to titrate medication. More on pediatric neurosurgery. Hector E. James, M.D., is an excellent speaker on any neuro or neurosurgical topics, pediatric brain development, intrauterine surgery, and especially (now) telemedicine. His email is: hector.james@jax.ufl.edu. I'm particularly interested in topics related to contraception and sexually transmitted diseases since I deal in college health mainly. More primary care topics n/a Neurology in Primary Care New treatment in DM. Rheumatology OA, Thyroid disease Obesity Obesity. Diabetes. Osteoporosis Obstructive sleep apnea Occult Stroke and TIA Ophthalmology Orthopedic evaluation for PCP. Evaluation of emergent situations in PCP setting Osteoporosis Diabetes Chronic Renal Failure Osteoporosis, acne, thyroid, triglyceridemia Pain management Pcos treatment Pain management Pain management in the elderly. Use of nutritional supplements proven by evidence based medicine Procedure labs procedures such as suturing, toenail removal etc Psychiatric medications for Dementia RAAS system; Hyperkalemia; hyperaldosteronism and resistant HTN Recommend doing bladder education first so you don't have to urinate during the lecture! Clinical practices that can easily be implemented without needed prior authorization Schizophrenia. HTN Sexual dysfunction, abnormal vaginal bleeding, some GYN issues, CRF Sexual health- male and female Sleep apnea, hepatic encephalopathy, new Rx for Hepatitis C and HIV, update on HTN Some Dermatology. Pain management STEMI auidelines **AFIB** LVADs Stroke, CVA, COPD Stroke, prophylaxis and treatment Stroke, thyroid disorders Thyroid disorder. Depression

Thyroid disorders, Dermatology - rashes, molluderm, contagious

Ulcerative colitis. Atrial fibrillation
Update on cancer treatments
Women's Health. Dermatology. Pediatric patients
Women's Health. Migraine. Depression. DM. Obesity
Women's Health Medical Diagnoses

Additional comments:

Comment

Absolutely superb! Great job, Sherman! Saw your NACE conference brochure - flew here from Modesto. And U of M beat Illinois 41-8! Class of 1971

Appreciate the sponsorship who fund registration fees and snack/lunch

Cardiovascular topics seem very specialized - looking for more general/Primary Care-oriented presentations

Did have difficulty with the video, had to read most of the content

Dr. Gillespie's first lecture VERY technically challenging. Went through a lot of trials and difficult to follow. Think it is very important to discuss heart failure in African American population

Dr. Watson's speech was slurred and affect was interesting.

Enjoyable! Thank You!

Enjoyed and learned from all speakers, but really enjoyed and kept my attention was dual presentations of Dr. Watson and Dr. Gillespie

Excellent

Excellent for this practical medical activity

Excellent, relevant topics to Primary Care

Excellent.please send me invite for simulant participation

Great conference!

Great program

Great show

Great speakers - not so great food (breakfast and lunch)

Great speakers full of energy and very passionate about their respective subjects, worth every minute of my Saturday's to listen and learn.

Heart failure talks were informative, but in a limited amount of time would have rather seen topics more applicable to Primary Care - heart failure treatment is usually optimized by cardiologists, not PCPs

HF lecture needs break/stretch break in between

HF management may be beyond my scope - not as relevant to me as other lectures. Overall, excellent conference though. Thank you very much!

I always enjoy the lecture and update EBM to enhance my knowledge in Primary Care since I practice/specialize in Neurology

I am sure Dr. Gillespie's talks were great, but they were way over my head and there were no results for me to refer to, otherwise I could have absorbed what he said since it was out of my field with drugs I don't use. Second talk better, maybe it was sinking in!

I reall appreciate have these presentations. I have learned a lot from participating.

I really liked being given the option to do the Cme from live webcast and really lik d being able to participate in questions voting. However it will be more helpful f the percentages w live audience were combined.

n/a

Need to offer WiFi code so slides can be viewed online while at conference. Rosenberg kept mentioning urologists not calling him but the AUA does have resources for PCP's

Nice presentation

None

One of the best presentations I have been in attendance for

Prostate cancer presentation could be far more concise. Leading toward 4K testing is very commercial. Dr. Gillespie - too many studies, more concise please, don't need all the proof presented. Too much focus on AA. Cardiac presentation too in depth for Primary Care. Dr. Watson concise and engaging

Sound system not very good. Specifically Dr. Gillespie was especially hard to hear/understand. Some slides were difficult to read

Thank you

Thank you for a well done conference. The faculty was excellent.

THANK YOU FOR THIS COMPLIMENTARY CME EVENT!

Thank you.

Thank you. Excellent presentation

Thank you. Excellent, thank you so much!

Thank you. Very educational. Lunch time nutrition talk was excellent

The best lecture I have ever heard on adult ADHD! Excellent, practical, evidence-based, but user friendly presentation on heart failure. Merci beaucoup!

THE PRESENTERS WERE VERY KNOWLEDGEABLE & ENGAGING. THE TOPICS ARE WELL COVERED & PRESENTED. THE WHOLE EVENT WAS WELL PLANNED & EXECUTED. THE TIMING ESPECIALLY BEING ON A WEEKEND HELPED TREMENDOUSLY.

Too many acronyms on slides - please simplify. Liked back and forth with cardiologists

Truly fabulous speakers. Have Gillespie and Watson start together at HF1 - he is too dry by himself but quite good with her. The quizzes are very good learning tools

Very good presentations, good practical information

Very informational

Very irritating when the programs run over the allotted time and start and end late. The presenters do not need to answer ever single question people ask. This was a problem for me when the conference ended almost and hour late.

Wish speakers to talk more clearly. Thank you!